Epoch 15: Drug Prices are NOT Justified by R&D Spend

The Cost of Innovation & Arguments Against Pharma R&D

Welcome to the 23 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,110 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. This week we discuss a controversial, but important topic - drug pricing.  The discussion will center around reviewing a contrarian view recently proposed by Angelis et. al., and published in the British Medical Journal.  It is important to LISTEN to the other side of the argument in order to understand the underlying assumptions.  Once the basis for the position is understood we can raise counter arguments.  This is how dialog in the scientific open square is supposed to work and has worked for decades until recently - we won't go into this topic further other than to highlight our purpose is simply to highlight the other side of a controversial topic and to provide counter arguments to this paper in a respectful way.

We are now operating under a hybrid subscription model where the Sunday update has moved under the paywall - a BIG THANK YOU to those that have joined. The Thursday market update will continue to remain free. The more forward looking content, the insider insights, and market data you need to really assess what is happening in the world of biotech will shift to Sundays.  

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients.  Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.

Go forward we will be making announcements regarding significant public biotech trading opportunities via substack ALERT special posts.  This will focus primarily on the major market moving biotech events and will likely be centered around data readouts from the major scientific conferences.  We will not offer trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely drive stock prices +/-100% in either direction.  Be sure to SUBSCRIBE to not miss.

Enough shilling for the day, lots to cover this week, let's get started!